Brief: Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation For Zagociguat

Korsana Biosciences

27/03/2023 15:21

March 27 (Reuters) - Cyclerion Therapeutics Inc
 CYCN.O :
    * CYCLERION THERAPEUTICS RECEIVES U.S. FDA ORPHAN DRUG
DESIGNATION
FOR ZAGOCIGUAT FOR THE TREATMENT OF MITOCHONDRIAL DISEASES
    * CYCLERION THERAPEUTICS RECEIVES U.S. FDA ORPHAN DRUG
DESIGNATION
FOR ZAGOCIGUAT FOR THE TREATMENT OF MITOCHONDRIAL DISEASES

Source text for Eikon:  ID:nGNX1RBLr5 
Further company coverage:  CYCN.O